THE REINVAD LVAD – SMART TECHNOLOGY TO ENHANCE LONG-TERM CIRCULATORY SUPPORT THERAPY

Despite the growing acceptance of LVAD therapy, concerns relating to adverse events have been raised. Fields such as implantation techniques, patient management and patient selection pose opportunities to advance outcomes, however, new and enhanced device technology, such as the ReinVAD LVAD, will h...

Full description

Saved in:
Bibliographic Details
Published in:International journal of artificial organs 2019-08, Vol.42 (8)
Main Authors: Schmitto, J, Graefe, R, Krämer, M, Aushorn, J, Keusch, L, Grüterich, M, Henseler, A, Haverich, A, Körfer, R
Format: Article
Language:English
Subjects:
Blood pumps
Centrifugal pumps
Clinical trials
Coagulation
Controllers
Implantation
Multidisciplinary research
Pressure
Pressure effects
R&D
Regulatory approval
Research & development
Sheep
Technology
Therapy
Thrombosis
Transplantation
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite the growing acceptance of LVAD therapy, concerns relating to adverse events have been raised. Fields such as implantation techniques, patient management and patient selection pose opportunities to advance outcomes, however, new and enhanced device technology, such as the ReinVAD LVAD, will have to contribute to improve and grow the therapy. The ReinVAD GmbH was founded as spin-off company of the Helmholtz-Institute of the RWTH Aachen University, Germany, and leads the development project to regulatory approval and clinical application. The core technology is a miniaturized, 3rd generation, centrifugal blood pump. It is the result of a multidisciplinary research and development program equipping the system with features that will improve outcome for bridge to transplantation and especially destination therapy patients. Chronic trials typically up to 90 days in a sheep confirm the capabilities of the system with excellent resistance to thrombogenicity since no design related thrombus could be found despite ceased anti-coagulation after 6 weeks. Implemented features are a pump for partial and full support with flow up to 10 l/min, a fully integrated flow sensor, an implantable driveline connector, a highly pressure-sensitive pump characteristic, an automated speed controller and a user-friendly one-piece extracorporeal system. The sensor provides real flow measurements. The driveline connector ensures easy exchange in case of infections and renders the system ready-for-TET. The pump pressure sensitivity, among other effects, leads to increased exercise capacity and arterial pulsation. The controller ensures that the pump always operates at its optimal speed. The one-piece extracorporeal system reduces use errors and improves satisfaction with this component of everyday life. The results indicate that the ReinVAD LVAD will be an effective system to enhance long-term circulatory support therapy.
ISSN:0391-3988
1724-6040